ARTICLE | Clinical News
Oral Relistor methylnaltrexone regulatory update
July 13, 2015 7:00 AM UTC
Valeant submitted an NDA to FDA for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. A subcutaneous formulation of the peripher...